Subsequent results showed that overexpression of FGD5-AS1 results in decreased ALP activity and calcium nodules, as well as expression of RUNX2 and OPN, thereby alleviating CAVD. The gene discussed is FGD5; the disease is congenital bilateral aplasia of vas deferens from CFTR mutation.